143 related articles for article (PubMed ID: 31977753)
1. The significance of serum thyroglobulin measurement before and after the treatment of toxic nodular goiter with 131I.
Bonefačić B; Crnčić TB; Tomaš MI; Girotto N; Ivanković SG
Nucl Med Commun; 2020 Apr; 41(4):344-349. PubMed ID: 31977753
[TBL] [Abstract][Full Text] [Related]
2. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
3. [Pre- and postoperative thyroglobulin secretion into the blood in nodular goiter].
Gemsenjäger E; Girard J; Martina B
Schweiz Med Wochenschr; 1984 Jun; 114(23):826-9. PubMed ID: 6740300
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
5. Effect of therapy on the serum thyroglobulin concentration in patients with toxic diffuse goiter, toxic nodular goiter and toxic adenoma.
Ericsson UB; Tegler L; Dymling JF; Thorell JI
J Endocrinol Invest; 1987 Aug; 10(4):351-7. PubMed ID: 2445808
[TBL] [Abstract][Full Text] [Related]
6. Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter.
Mojsak MN; Abdelrazek S; Szumowski P; Rogowski F; Sykała M; Kostecki J; Kociura-Sawicka A; Jurgilewicz D; Myśliwiec J
Nucl Med Rev Cent East Eur; 2016; 19(1):3-11. PubMed ID: 26841373
[TBL] [Abstract][Full Text] [Related]
7. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
8. [Autoimmunization and multinodular large toxic goiter therapy using repeated doses of 131I].
Pisarek M; Baczyk M; Gryczyńska M; Pietz L; Ziemnicka K; Sowiński J
Pol Arch Med Wewn; 2006 Jun; 115(6):545-50. PubMed ID: 17263226
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
Nygaard B; Jarløv AE; Kristensen LO; Faber J
Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine therapy for multinodular toxic goiter.
Nygaard B; Hegedüs L; Ulriksen P; Nielsen KG; Hansen JM
Arch Intern Med; 1999 Jun; 159(12):1364-8. PubMed ID: 10386513
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin.
Rubio IG; Silva MN; Knobel M; Romão R; Possato R; Gebrin EM; Buchpiguel C; Medeiros-Neto G
J Endocrinol Invest; 2007; 30(7):535-40. PubMed ID: 17848834
[TBL] [Abstract][Full Text] [Related]
12. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres.
Silva MN; Rubió IG; Romão R; Gebrin EM; Buchpiguel C; Tomimori E; Camargo R; Cardia MS; Medeiros-Neto G
Clin Endocrinol (Oxf); 2004 Mar; 60(3):300-8. PubMed ID: 15008994
[TBL] [Abstract][Full Text] [Related]
13. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
14. Serum thyroglobulin level in patients with diffuse and nodular goiter, after therapeutic application of stable iodine.
Djurica SN; Cirović M; Tasovac-Ponomarev D
Exp Clin Endocrinol; 1992; 99(1):21-5. PubMed ID: 1628693
[TBL] [Abstract][Full Text] [Related]
15. [The treatment of multinodular large non-toxic goiter using repeated doses of radioiodine (preliminary report)].
Pisarek M; Baczyk M; Gryczyńska M; Sowiński J
Endokrynol Pol; 2007; 58(1):18-26. PubMed ID: 17354201
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.
Erem C; Kandemir N; Hacihasanoglu A; Ersöz HO; Ukinc K; Kocak M
Endocrine; 2004 Oct; 25(1):55-60. PubMed ID: 15545707
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of radioiodine therapy in multinodular toxic goiter, applying an implemented dose calculation algorithm.
Schiavo M; Bagnara MC; Camerieri L; Pomposelli E; Giusti M; Pesce G; Reitano C; Caputo M; Bagnasco M
Endocrine; 2015 Apr; 48(3):902-8. PubMed ID: 25151403
[TBL] [Abstract][Full Text] [Related]
19. Long-term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity.
Roque C; Santos FS; Pilli T; Dalmazio G; Castagna MG; Pacini F
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32320467
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of factors affecting treatment results for toxic goiter with radioactive 131I].
Listewnik MH
Ann Acad Med Stetin; 2000; 46():109-21. PubMed ID: 11712298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
